Advanced
Endovascular
Therapy of Aortic
Disease
Advanced Endovascular Therapy of Aortic Disease

EDITED BY

Alan B. Lumsden, MD, ChB
Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy
Michael E. DeBakey Department of Surgery, Baylor College of Medicine
Houston, TX, USA

Peter H. Lin, MD
Chief of Vascular Surgery, Michael E. DeBakey Veterans Affairs Medical Center
Chief of Interventional Radiology, Michael E. DeBakey Veterans Affairs Medical Center
Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy
Michael E. DeBakey Department of Surgery, Baylor College of Medicine
Houston, TX, USA

Changyi Chen, MD, PhD
Professor of Surgery & Molecular and Cellular Biology, Director, Molecular Surgeon Research Center
Vice Chairman, Surgical Research, Division of Vascular Surgery and Endovascular Therapy
Michael E. DeBakey Department of Surgery, Baylor College of Medicine
Houston, TX, USA

Juan C. Parodi, MD
Professor of Surgery
Chief of Endovascular Surgery
Division of Vascular & Endovascular Surgery Department of Surgery
University of Miami Medical School
Miami, FL, USA

Blackwell Futura
Contents

Acknowledgments, vii
Contributors, ix
Preface, xiii

Part I Natural history and preoperative planning

1 Etiology and pathogenesis of aortic disease, 3
   Bo Risberg & Lars Lönn

2 Clinical consideration of aortic disease: atherosclerosis, aneurysm, dissection, and traumatic injury, 11
   Lars Lönn, & Bo Risberg

3 Thoracic aortic aneurysms: classification, incidence, etiology, natural history, and results, 25
   Hazim J. Safi

4 Angiographic aortic anatomy and variants, 31
   Louis G. Martin

5 Patient selection for thoracic endografts: today and tomorrow, 41
   Mark A. Farber

6 Noninvasive aortic imaging modalities: CT, MRI, intravascular ultrasound (IVUS), and transesophageal echocardiography (TEE), 45
   Tae K. Song, & Rodney A. White

7 Preoperative imaging and device sizing in endovascular management of thoracic aortic aneurysms, 53
   Panagiotis Kougioum, Hosam El Sayed, & Wei Zhou

8 Intramural hematoma and penetrating ulcer, 61
   Michael D. Dake

9 Patient follow-up and evaluation of abdominal and thoracic stent grafts, 65
   Jan D. Blankenstein

Part II Thoracic aortic aneurysm

10 Endovascular therapy of thoracic aneurysms: Gore TAG trial results, 75
    Jae-Sung Cho, Shan-e-ali Haider, & Michel S. Makaroun

11 Medtronic TALENT and VALIANT devices: moving toward the next generation of thoracic aortic stent grafts, 85
    Ron Fairman

12 Early clinical experience with the Bolton Relay thoracic stent graft, 91
    Frank J. Criado

13 Clinical results of the EUROSTAR thoracic registry, 95
    Peter Harris, Lina Leurs, Randolph Statius van Eps, & Jacob Buth

14 Management of aortic aneurysms and dissections with the Zenith TX2 stent graft, 105
    W. Anthony Lee

Part III Aortic dissection and traumatic aortic injury

15 Aortic dissection: evaluation and management—choosing the right intervention, 117
    David M. Williams

16 Aortic dissection: role of fenestration and stents in the endograft era, 123
    David M. Williams
17 Blunt trauma to the thoracic aorta: current challenges, 127

18 Traumatic disruption of the aorta, 135
    Ross Milner, Karthik Kasirajan, & Elliot Chaikof

19 Should endovascular repair be considered the standard treatment in traumatic thoracic aortic injury? 141
    Peter H. Lin, Tam T. Huynh, & Eric K. Peden

Part IV Techniques, new devices, and surveillance

20 Site-specific aortic endografting: case examples and discussion—the ascending aorta, 155
    Edward B. Diethrich

21 Improved endograft fixation—a role for aortic endostapling? 169
    Brian R. Hopkinson

22 Treating smaller aneurysms: is there a rationale? 175
    Kenneth Ouriel

23 Management strategies, adjuncts, and technical tips to facilitate endovascular treatment of ruptured abdominal aortic aneurysms, 181
    Frank J. Veith, Nicholas J. Gargiulo III, & Evan C. Lipsitz

24 Postoperative imaging surveillance and endoleak management after endovascular repair of thoracic aortic aneurysms, 187
    S. William Stavropoulos, & Jeffrey P. Carpenter

25 Percutaneous repair of abdominal aortic aneurysms with local anesthesia and conscious sedation, 193
    Zvonimir Krajcer, Neil E. Strickman, Ali Mortazavi, & Kathryn Dougherty

26 Endoleak management in the abdominal aorta, 199
    Jennifer L. Ash, Syed M. Hussain, & Kim J. Hodgson

27 Aneurysm sac pressure measurement with a pressure sensor in endovascular aortic aneurysm repair, 209
    Lisandro Carnero & Ross Milner

Index, 217
We would like to thank all the faculty contributors for their tireless efforts in the preparation of the chapters. We are indebted to Yvette Whittier, our administrative coordinator, for her countless hours of hard work in bringing this project together. Last, but not least, we are grateful to our families, Cathy, Aaron, Amber, Donal, Sarah, Terry, Mark, Pete, and Cynthia, for their patience and support in making this book a reality.
Contributors

Jennifer L. Ash, MD
Department of Surgery
University of Illinois College of Medicine
Peoria, IL
USA

Jan D. Blankensteijn, MD
Department of Vascular Surgery
Radboud University Nijmegen Medical Centre
Nijmegen
The Netherlands

Jacob Buth, MD
Catharina Hospital
Eindhoven
The Netherlands

Lisandro Carnero, MD
Division of Vascular Surgery
Department of Surgery
Emory University School of Medicine
Atlanta, GA
USA

Jeffrey P. Carpenter, MD
Department of Surgery
Hospital of the University of Pennsylvania
Philadelphia, PA
USA

Elliot Chaikof, MD, PhD
Division of Vascular Surgery
Department of Surgery
Emory University School of Medicine
Atlanta, GA
USA

Jae-Sung Cho, MD
Division of Vascular Surgery
Department of Surgery
University of Pittsburgh School of Medicine
Pittsburgh, PA
USA

Frank J. Criado, MD
Division of Vascular Surgery
Department of Surgery
Union Memorial Hospital-MedStar Health
Baltimore, MD
USA

Michael D. Dake, MD
Professor of Radiology, Internal Medicine (Pulmonary Disease), Surgery;
Chairman of the UVA Department of Radiology and the
Harrison Medical Teaching Professor of Radiology
Charlottesville, VA
USA

Edward B. Diethrich, MD
Arizona Heart Institute and Arizona Heart Hospital
Phoenix, AZ
USA

Kathryn Dougherty, RN
Department of Cardiology
St. Luke’s Episcopal Hospital
The Texas Heart Institute
Houston, TX
USA

Hosam El Sayed, MD
Division of Vascular Surgery and Endovascular Therapy
Michael E. DeBakey Department of Surgery
Baylor College of Medicine
Houston, TX
USA

Ron Fairman, MD
Division of Vascular Surgery
Department of Surgery
University of Pennsylvania
Philadelphia, PA
USA

Mark A. Farber, MD
Division of Vascular Surgery
Department of Surgery
University of North Carolina
Chapel Hill, NC
USA
Richard G. Fisher, MD
Department of Radiology
Baylor College of Medicine
Houston, TX
USA

Nicholas J. Gargiulo III, MD
Division of Vascular Surgery
Department of Surgery
Montefiore Medical Center
New York, NY
USA

Shan-e-ali Haider, MD
Division of Vascular Surgery
Department of Surgery
University of Pittsburgh School of Medicine
Pittsburgh, PA
USA

Peter Harris, MD, FRCS
Regional Vascular Unit
Royal Liverpool University Hospital
Liverpool
UK

Kim J. Hodgson, MD
Division of Vascular Surgery
Department of Surgery
Southern Illinois University
Springfield, IL
USA

Brian R. Hopkinson, MD
Division of Vascular Surgery
Department of Surgery
University of Nottingham
Queen’s Medical Centre
Nottingham
UK

Syed M. Hussain, MD
Vascular and Endovascular Surgery
HeartCare Midwest
Assistant Clinical Professor of Surgery
University of Illinois College of Medicine at Peoria
Peoria, IL, USA

Tam T. Huynh, MD
Division of Vascular Surgery and Endovascular Therapy
Michael E. DeBakey Department of Surgery
Baylor College of Medicine
Houston, TX
USA

Karthik Kasirajan, MD
Division of Vascular Surgery
Department of Surgery
Emory University School of Medicine
Atlanta, GA
USA

Panagiotis Kougias, MD
Division of Vascular Surgery and Endovascular Therapy
Michael E. DeBakey Department of Surgery
Baylor College of Medicine
Houston, TX
USA

Zvonimir Krajcer, MD
Department of Cardiology
St. Luke’s Episcopal Hospital
The Texas Heart Institute
Houston, TX
USA

W. Anthony Lee, MD
Division of Vascular Surgery and Endovascular Therapy
University of Florida College of Medicine
Gainesville, FL
USA

Lina Leurs, MD
Catharina Hospital
Eindhoven
The Netherlands

Peter H. Lin, MD
Division of Vascular Surgery and Endovascular Therapy
Michael E. DeBakey Department of Surgery
Baylor College of Medicine
Houston, TX
USA

Evan C. Lipsitz, MD
Division of Vascular Surgery
Department of Surgery
Montefiore Medical Center
New York, NY
USA

Lars Lönn, MD, PhD
Departments of Radiology
Sahlgrenska University Hospital
Göteborg University
Göteborg
Sweden
Contributors

Michel S. Makaroun, MD
Division of Vascular Surgery
Department of Surgery
University of Pittsburgh School of Medicine
Pittsburgh, PA
USA

Louis G. Martin, MD
Vascular and Interventional Radiology
Department of Radiology
Emory University School of Medicine
Atlanta, GA
USA

Kenneth L. Mattox, MD
Michael E. DeBakey Department of Surgery
Baylor College of Medicine
Houston, TX
USA

Ross Milner, MD
Division of Vascular Surgery
Department of Surgery
Emory University School of Medicine
Atlanta, GA
USA

Ali Mortazavi, MD
Department of Cardiology
St. Luke’s Episcopal Hospital
The Texas Heart Institute
Houston, TX
USA

Kenneth Ouriel, MD
Division of Surgery
The Cleveland Clinic
Cleveland, OH
USA

Eric K. Peden, MD
Division of Vascular Surgery and Endovascular Therapy
Michael E. DeBakey Department of Surgery
Baylor College of Medicine
Houston, TX
USA

Bo Risberg, MD, PhD
Departments of Surgery
Sahlgrenska University Hospital
Göteborg University
Göteborg
Sweden

Hazim J. Safi, MD, FACS
Department of Cardiothoracic and Vascular Surgery
The University of Texas Medical School at Houston
Memorial Hermann Heart and Vascular Institute
Houston, TX
USA

Tae K. Song, MD
Division of Vascular Surgery
Department of Surgery
Harbor-UCLA Medical Center
Torrance, CA
USA

Randolph Statius-van Eps, MD
Catharina Hospital
Eindhoven
The Netherlands

S. William Stavropoulos, MD
Departments of Radiology
Hospital of the University of Pennsylvania
Philadelphia, PA
USA

Neil E. Strickman, MD
Department of Cardiology
St. Luke’s Episcopal Hospital
The Texas Heart Institute
Houston, TX
USA

Frank J. Veith, MD
Department of Vascular Surgery
The Cleveland Clinic
Cleveland, OH
USA

Matthew J. Wall, Jr., MD
Michael E. DeBakey Department of Surgery
Baylor College of Medicine
Houston, TX
USA

Cliff Whigham, DO
Department of Radiology
Baylor College of Medicine
Houston, TX
USA

Rodney A. White, MD
Division of Vascular Surgery
Department of Surgery
Harbor-UCLA Medical Center
Torrance, CA
USA
David M. Williams, MD
Division of Interventional Radiology
Department of Radiology
University of Michigan
Ann Arbor, MI
USA

Wei Zhou, MD
Division of Vascular Surgery and Endovascular Therapy
Michael E. DeBakey Department of Surgery
Baylor College of Medicine
Houston, TX
USA
Since the concept of using an endovascular stent-graft to repair an abdominal aortic aneurysm was initially described by Dr. Parodi and Dr. Palmaz, this treatment strategy has undergone a dramatic technological evolution. This evolution is further fueled by the increased public acceptance of this minimally-invasive therapy, miniaturization of endovascular stent-grafts, and availability of multiple devices approved by the Food and Drug Administration (FDA). Growing evidence clearly supports the early treatment success of this treatment strategy, in terms of morbidity and mortality reduction, when compared to the conventional open repair in well-selected patient cohorts. Advances in this endovascular technology have also broadened the treatment armamentarium of thoracic aortic pathologies. Since the FDA has approved the use of endovascular repair of descending thoracic aneurysms, many researchers have found a beneficial role of using this technology in the treatment of other thoracic aortic pathologies, including dissection and traumatic transection.

Treatment outcome of endovascular repair of aortic diseases is highly dependent on the appropriate patient selection, physician's experience, and post-procedural device surveillance. Disseminating the clinical experiences from physician experts in this field will undoubtedly educate other endovascular interventionalists and potentially improve treatment outcome for all physicians who perform endovascular aortic procedures. The basis of this book “Advanced Endovascular Therapy of Aortic Disease” represents the collection of clinical experiences from a group of well-known endovascular interventionalists who participated in the 2006 Total Endovascular Aorta Symposium, sponsored by the Division of Vascular Surgery and Endovascular Therapy of the Baylor College of Medicine. A total of 26 chapters are included which cover four sections, including natural history and preoperative planning, thoracic aortic aneurysm, aortic dissection and traumatic aortic injury, and techniques, new devices, and surveillance.

It is our hope that the collection of these chapters provided by faculty experts in the field of endovascular aortic therapy as assembled in this symposium will help to enhance the practice of endovascular interventionalists. It is our sincere privilege to put forth this compendium book as a token of their contributions to the field of endovascular aortic therapy.

Alan B. Lumsden, MB, ChB
Peter H. Lin, MD
Changyi Chen, MD, PhD
Juan C. Parodi, MD
PART I

Natural history and preoperative planning
The aorta can be affected by a variety of pathological conditions. Some of them have a clear genetic component and affect young patients or patients in the early adolescence. Most pathology is however encountered in the grown-up population and is caused by degenerative diseases. This chapter will focus on the following pathological conditions that affect the aorta: atherosclerosis, aneurysms, dissections, Marfan’s syndrome, Ehlers–Danlos syndrome, and Takayasu’s disease.

Atherosclerosis

Atherosclerosis is a systemic and generalized disease that is the main cause for premature death in the adult population in the Western world. Several vascular beds are affected simultaneously, the heart, brain, viscera, and extremities. The pathophysiology of atherosclerosis in large arteries, such as aorta, is not different from that in small vessels. The etiology of atherosclerosis is extremely complex. Despite intense research there is still a long way to go before we have a good understanding of the disease that is reflected in new preventive and therapeutic strategies. The atherosclerotic process involves predominantly the intimal and medial layers of the wall.

The response to injury hypothesis proposed by Ross has had a heavy input on atherosclerotic research [1, 2]. It has stimulated research on endothelial interaction with blood cells and signaling to smooth muscle cells. An initial event is some sort of injury to the endothelium leading to permeability alterations allowing passage of large molecules such as lipids. The injury may not be mechanical. Low-density lipoproteins in hypercholesterolemic patients can in itself cause endothelial injury.

Fatty streak and fibrous plaque

The intimal layer with the endothelial cells is the first line of defense against atherosclerosis. The very first event is the fatty streak which consists of lipid accumulation in macrophages located in and beneath the endothelium [3]. Depending on genetics and life style, the fatty streak may either regress or progress into atheroma. Progression of lipid accumulation leads to focal intimal thickenings. Formation of fibrous plaques is usually not seen until in the fourth decade. Fibrotic tissue and smooth muscle cells form a fibrous cap surrounding the lipid core. There is a necrotic center of amorphous material, extracellular proteins, matrix fibers, lipid-containing cells, cholesterol crystals, and calcium salts. The plaques are infiltrated with vasa vasorum. The lipid-rich core is extremely thrombogenic due its high content of tissue factor. An intact fibrous cap prevents release of procoagulative activity.

The lesions can be characterized as soft or hard. The soft plaques are dominated by lipid deposition in the necrotic core. They are particularly prone to rupture leading to thrombotic complications. The hard sclerotic lesions are characterized by
Inflammation and plaque

The involvement of inflammatory cells as well as their activation has put forward the hypothesis of inflammation as an initial event in atherosclerosis. The atheromatous plaque consists of a core of foam cells and lipids. The border regions, shoulders, of the plaque are made up of inflammatory cells such as T-cells, macrophages, and mast cells [4]. These cells produce cytokines as signs of activation [5]. The plaques are predominantly located in areas of flow disturbances such as branches. The macrophages produce PDGF as a mitogen, cytokines and growth factors. Interleukin 1 (IL-1), tumor necrosis factor α (TNF-α), transforming growth factor β (TGF-β), and several others factors are produced. Through these mediators, the macrophages can affect and regulate cellular organization in the plaque. The macrophages may be antigen presenting cells to T-lymphocytes that participate in the inflammatory process. Oxidized LDL is such an antigen that can trigger the inflammation [6].

Role of the endothelium

The integrity of the endothelium is essential in preventing the initial developments of the plaque. Perturbation of the endothelium causes expression of growth factors that stimulate proliferation of smooth muscle cells. Likewise adhesion molecules are expressed on the endothelial surface causing cellular interactions. Platelets adhere to the endothelium through expression of their surface glycoproteins Ib and IIb/IIIa. Specific adhesion molecules such as selectins are involved in leukocyte rolling on the surface followed by sticking and extravasation of the cells. VCAM-1, vascular cell adhesion molecule, adheres monocytes and lymphocytes and is upregulated by high cholesterol levels. Activated adhering cells and cells in the vessel wall release inflammatory mediators, e.g., cytokines. Proteolytic enzymes, metalloproteinases (MMPs), and their inhibitors are activated and contribute to the development of the plaque by facilitating migration and proliferation of cells.

Recent research has demonstrated the importance of a variety of immune cells in the atherosclerotic process. T-cells activated from antigens release cytokines, which trigger activation of macrophages and other vascular cells. The process is balanced by regulatory T-cells, which produce IL-10 and TGF-β, both anti-inflammatory mediators. Release of inflammatory cytokines especially IL-6 will stimulate production of CRP in the liver. An excellent and comprehensive review of inflammation and atherosclerosis was recently published [7].

Plaque rupture

There is an overwhelming body of knowledge on the role of plaque rupture to initiate thrombosis and ischemia [8]. Most of the data stems from coronary arteries but the process does not differ in other parts of the vascular system.

The lipid core of the plaque is highly thrombogenic due to its content of tissue factor. When the lipid is sealed in its fibrous cap, it is harmless but when released it initiates an immediate and very strong coagulation. Activated macrophages in the plaque express tissue factor, which further enhances the thrombotic state.

The shoulders of the plaque are at risk for rupture. Cytokine-mediated cell activation leads to proteolytic degradation of the matrix particularly in the shoulder region. MMPs are key players in these events. Functional polymorphism in several MMP genes is associated with atherosclerotic manifestations and complications such as coronary thrombosis, myocardial infarction, stenosis, arterial stiffness, and blood pressure [9]. MMP genotyping can probably be of importance in the clinical management of cardiovascular patients in the future.

In small arteries such as the coronaries, plaque rupture can lead to thrombotic occlusion. In larger arteries including the aorta, this can occur as well only if there is a pronounced stenosis. More often plaque rupture will cause ulceration with thrombotic depositions and subsequent risk for embolization.

Degeneration of the plaque

Degeneration of the plaques can occur from necrotic changes in the plaque. Insufficient circulation through the vasa vasorum causes ischemia. Activated MMPs degrade the extracellular matrix thereby contributing to the plaque destabilization. The plaque degeneration can lead to ulceration or calcification. They cause stenosis and, depending on the degree of flow impairment, ischemia.
other complications such as thrombosis or embolization of thrombotic or atheromatous material.

**Plaque and flow**

The likelihood of developing atherosclerotic lesions differs between arteries at various locations. Plaques develop in relation to branches, twists, and bends. Typically they are found in the proximal, upstream part of the orifice. One common feature is flow disturbances with turbulence, flow separation, and low shear stress. Shear stress influences directly the endothelium, which leads to increased permeability and altered cellular functions such as expression of nitric oxide and adhesion molecules. Plaques localize predominantly in areas with low shear stress while areas of high shear stress are relatively spared from atherosclerosis [10].

Formation of a stenotic plaque does not initially encroach on the luminal transverse area and volume. There is a compensatory enlargement of the artery to accommodate the plaque without affecting flow. Usually the plaque is eccentric in the vessel leaving a rounded lumen but an oval vessel. This has been demonstrated in different parts of the vascular tree. Large plaques may however encircle the whole circumference and cause a stenosis [11].

Constriction and dilatation, mediated through the endothelium, are means of keeping wall shear stress constant [12].

**Infection and atherosclerosis**

The strong inflammatory components of the disease have put forward the intriguing question of an infectious etiology to atherosclerosis. Virus and bacteria have been found in diseased vessel wall. Until now a causative role has not been established. *Chlamydia pneumoniae* is found in a large number of patients with atherosclerosis. About 60% of these patients are seropositive. No relations have been found between symptoms, degree of atherosclerosis, and extent of *C. pneumoniae* involvement [13]. Similarly, no correlation was found between plaque destabilization and herpes simplex or cytomegalovirus seroreactivity.

A few studies have been published on effects of antibiotics against *C. pneumoniae* for prevention of coronary events and with negative results [14, 15]. *Chlamydia* may not be the cause of atherosclerosis but can speed up the development and progression of the disease [16], perhaps by enhancing the inflammatory reaction. Much of this basic research will of course have implications on the future therapeutic strategy.

**Atherosclerosis in different parts of the aorta**

The manifestations of atherosclerosis differ not only in different vascular regions such as carotid, coronary, and femoral arteries but also in various parts of the aorta.

The infrarenal abdominal aorta is a frequent site of plaques with or without ulcerations. Ulcerated areas are covered by thrombotic material. Embolization from these areas can cause focal ischemia in the lower extremities. Often there is a heavy calcification. The stenotic lesions can develop into total occlusions. The atherosclerotic process causes medial degeneration with risk for dilatation while the thoracic aorta is relatively spared these severe manifestations.

These findings could be due to different architecture in the thoracic and the abdominal aorta. The vascular nutrition differs in these two regions of the aorta. In the thoracic aorta, the main part of the vessel wall is supplied by vasa vasorum. The abdominal aorta lacks vasa vasorum and relies on diffusion of oxygen and nutrients from the lumen. The likelihood of ischemia in this part of the aorta is thus greater and this can contribute to the degeneration of the wall.

**Risk factors for atherosclerosis**

Several risk factors for atherosclerosis have been identified. Most are associated with the metabolic syndrome and they are all lifestyle associated. The metabolic syndrome is already a widespread condition affecting 10–25% of western populations and its prevalence is increasing. Adipositas, hypertension, hyperlipidemia, and type-2 diabetes are dominating components of this syndrome. The attractiveness of the metabolic syndrome as an entity lies in the assumption that the syndrome has greater power to predict morbidity and mortality than individual components themselves.

Smoking initiates the atherosclerotic process at an earlier stage and accelerates its progression. Smoking is probably the most important factor in the development of atherosclerosis. The mechanistic
details are still unknown but it is likely that oxygen-free radicals play a role. Cessation of smoking decreases the risk for clinical manifestations of atherosclerosis probably by arresting the progression of the lesions.

The role of lipids
Disturbances in lipid metabolism have since long been associated with atherosclerosis. High cholesterol levels lead to accumulation of cholesterol esters in macrophages, which are turned into foam cells. High levels of LDL can change the endothelial barrier, particularly oxidized LDL can be noxious to the endothelium. Modified LDL can via scavenger receptors be taken up by macrophages leading to formation of foam cells.

The hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are effective in LDL lowering. The enzyme is the rate-limiting step in the cholesterol synthesis. Another action, probably of equal importance, is its anti-inflammatory effect. Through this mechanism, the very early events in atherogenesis can probably be prevented.

Another exciting approach to treat atherosclerosis is by using recombinant Apo-AI Milano that in animal experiments can cause regression of atherosclerosis. It is a variant of apolipoprotein A-I identified in an Italian subpopulation characterized by low HDL and low incidence of atherosclerosis. The drug was recently found to reduce the atheroma volume in coronary arteries in a controlled randomized trial in humans [17].

Aneurysms
Aneurysms develop in the degenerated aorta. Atherosclerosis is the most common cause for degeneration of the wall. Genetic components have been identified in Marfan’s syndrome and Ehlers–Danlos disease. Even in the most common, degenerative, form of aortic aneurysms there is a genetic component. There is a clear familiar occurrence with a risk of about 25% for first-degree probands [18].

Degradation of elastin has been associated with dilatation while rupture of the wall is related to collagen degradation [19]. MMP-9 (gelatinase B) that degrades elastin, collagen type IV, fibronectin, and other matrix proteins has been linked to aneurysmal disease. High levels of MMP-9 and MMP-3 have been found in abdominal aortic aneurysmal tissue [20, 21]. Levels of MMP-9 are associated with aneurysmal size [22].

Of particular interest is the importance of mutations in the genes coding for MMPs. Single nucleotide polymorphism in the MMP-9 gene at location-1562 (1562 bases from the start of the gene) has been associated with atherosclerosis and intracranial aneurysms. The latter is however controversial [23]. This mutation has been linked to aortic aneurysms in one study [24] while this was not confirmed in another investigation [25]. The latter study furthermore indicated that genetic variations in inhibitors of MMPs, TIMPs, were involved in aneurysm formation. More research is clearly needed to establish details of the genetic interplay in aortic aneurysms.

The aneurysmal pathology is characterized by a chronic inflammation with destruction of the extracellular matrix, remodeling of the wall layers, and reduction in number of smooth muscle cells. The smooth muscle cells are essential for production of extracellular matrix proteins. Less supportive scaffold enhances the degradation. The balance between MMPs and their inhibitors, TIMPs, is pivotal in the degradation of the wall. As the process progresses, dilatation occurs. This leads to flow disturbances, changes in wall tension with reduced tensile strength, and finally rupture. Therapeutic trials with doxycycline, a MMP inhibitor, are ongoing and preliminary results are encouraging with less progression of aneurysmal size in treated patients [26].

Dissections
Acute dissection can occur following degeneration with weakening of the wall. The most common form is the atherosclerotic variety typically seen in hypertensive patients. Lipid deposition, intimal thickening, fibrosis, and calcification are seen. The extracellular matrix is degraded with lysis of elastin, collagen breakdown, and cellular apoptosis. Through the action of MMPs the intima and vessel wall become fragile. The elastin synthesis may be inefficient. Macrophages, which express the elastin gene and produce tropoelastin, may play an important role by producing a defective elastin [27]. The histology is characterized by media necrosis, scarcity of smooth muscle cells, and loss of elastin [28].
Chapter 1 Etiology and pathogenesis of aortic disease

The polymerization of elastin is a very complicated process. Fibulin-5 is an extracellular protein expressed in the basement membrane in blood vessels. It is a key player in the synthesis of elastin. Patients with dissection in the thoracic aorta were recently found to have reduced levels of fibulin-5 [29]. This means that a low content of elastin in patients with dissection could be due to reduced synthesis, increased degradation or both.

Familial dissection in the ascending aorta (type A) was recently linked to a genetic mutation involving dysregulation TGF-β signaling. This suggests that TGF-β may have a critical role in this condition [30].

Obstruction of the vasa vasorum can cause local ischemia in the wall. The burden of mechanical stress in the hypertensive patient facilitates disruption.

The intramural hematoma is regarded as a special variety of a localized dissection even if this concept has been disputed recently [31]. The etiology may be disruption of a medial vasa vasorum causing a localized bleeding with hematoma. The intramural hematomas are particularly hazardous since approximately half of these patients go on to dissection or rupture [32].

Localized ulcers can occur in all parts of the aorta. They develop from plaque rupture and constitute weak points in the wall where a dissection can start.

There has been an interesting discussion on seasonal variation and the influence of atmospheric conditions on thoracic dissections. There seems to be a peak in wintertime [33, 34]. Atmospheric pressure and temperature seemed to be unrelated to aortic dissection in another recent study [35].

Marfan’s syndrome

Marfan’s syndrome is an autosomal dominant trait with main manifestations from the connective tissue with degeneration of the elastic fibers. The incidence is about 1/5000 inhabitants. Typically the main abnormalities are found in the cardiovascular, skeletal, and ocular systems.

Apart from mitral valve prolapse, dilatation of the aorta is typical for the cardiovascular involvement. The aortic dilatation is progressive and starts with enlargement of the sinuses of Valsalva. All parts of the aorta can be affected as the disease progresses distally. The most serious complications are dissection of the aorta or aneurysm formation with rupture. The patients are typically long and slender with arachnodactyly (long fingers). They have pectus excavatus, flat feet, and scoliosis. The ocular abnormalities are mainly lens luxation and myopia.

The aortic wall is thin with fragmentation of the elastic fibers in the medial layer. There is also defective synthesis and crosslinking of elastin. Collagen metabolism is affected as well with signs of increased collagen turnover (elevated hydroxyproline secretion in the urine and low proline/hydroxyproline ratio) [36].

The genetic defect responsible for Marfan’s syndrome has been localized to the fibrillin gene (FBN1) on chromosome 15. Fibrillin is a glycoprotein about 350 kD. A large number of mutations (>500) in the gene are found in Marfan patients. In the connective tissue there is a reduced fibrillin-1 deposition. This leads to defect fibrillin aggregation and crosslinking of elastin. Extracellular microfibrils are mainly made up of fibrillin. The defective microfibrils impair anchoring and structural maintenance in various tissues. The elastin formed is more easily degraded by MMPs. The weakness in the wall leads to aneurysmal dilatation and/or dissection.

Ehlers–Danlos syndrome

The Ehlers–Danlos syndrome is a genetically determined disease of the connective tissue. The main abnormalities are found in the described skin, joints, and arteries. Of all the 11 types of Ehlers–Danlos syndrome described, number IV is of particular interest from a cardiovascular point of view. This form is an autosomal dominant or recessive trait. The arterial manifestations make type IV particularly serious. The major cutaneous symptom is ecchymoses. Collagen type III synthesis is reduced in the arterial system. This renders the vessels thin and fragile. Especially the medial layer is thin with fragmentation of the internal elastic membrane.

Takayasu’s disease

Takayasu described this disease in 1908 [37]. It is characterized by a chronic inflammation that is predominantly localized to the arch. Synonymous names are “pulseless disease” or “aortic arch syndrome,” names that are quite descriptive of the nature of the disease. However, the disease is not
limited to the aortic arch but is found in most other large vessels. Women are much more frequently affected than men with a ratio of 4:1. The disease always starts before 40 years of age with a mean onset around 30. The incidence is 2–3 per million inhabitants in the USA.

**Macroscopic findings**

Stenotic processes that can involve all parts of the aorta and its main branches characterize the disease. The walls are thickened with perivascular sclerosis. The external diameter of the vessel is not affected. The stenotic process intrudes into the lumen and reduces the luminal surface area. In advanced cases, there may be complete occlusion. Typically there is a poststenotic dilation in Takayasu’s disease. Aortic aneurysms or dissection are not features of the disease. The supra-aortic branches are involved in 50% of the cases. The clinical symptoms depend on the extent and location of the lesions.

The typical lesions are usually seen in the arch and its branches but changes can occur in all other branches such as the visceral and the iliac vessels.

**Microscopic findings**

The most characteristic finding is that of a chronic inflammation. The most pronounced changes are seen in the adventitial and medial layers. The adventitia is site for a sclerotic collagenous dense tissue and with thickening of the vasa vasora. The media show breakage of the elastic fibers and with signs of neovascularization. The vessel wall is infiltrated with inflammatory cells, lymphocytes, histiocytes, and sometimes giant cells. The intima is grossly thickened with a loose connective tissue. The intimal changes are secondary to the pathological processes in the outer layers. Sometimes frank deposition of atherosclerotic material can be seen in the stenotic lesions. The histopathological changes can be related to the clinical stage. In the active phase, the findings of granulomas and infiltration with inflammatory cells are common. Later during the occlusive stage, the chronic inflammation with scarring is predominant.

The granulomatous appearance in the chronic stage has initiated speculations on tuberculosis being of etiological importance. Antigens from mycobacteria can cause granuloma. In recent clinical surveys, tuberculosis was found in 20% of the patients [38] and tuberculin test was positive in 47% [39]. The inflammatory component of the disease is further stressed by a correlation between IL-8 levels in plasma and degree of disease activity [40].

**References**